Featured Trial
Survey on COVID-19 Related Distress

Featured Trial
Self-Reported Data by Young Adults

Featured Trial
Prostate Cancer Prevention

Featured Trial
Myeloma Treatment

Featured Trial
Upper Urinary Tract Cancer Treatment

Clinical and Administrative Resources

Web Application Portal

Submit an Inquiry

Update My Roster Profile

Other Research Resources

Resources for Active Trials

Mentoring Program

Group Meeting Presentations, Audit Tools, and User Groups

Specialty Presentation:
Integrating PROs in Trials

Specialty Presentation:
PRO Research Overview

Specialty Presentation:
Implementation Science

About Us

The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1300 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More

Latest News

November 26, 2021

Treatment sequence impacts survival in BRAF-mutant metastatic melanoma

November 16, 2021

Press Release: Practice-changing trial results for advanced skin cancer

November 15, 2021

Press Release: Dr. Schnall to continue as Group Co-Chair

November 12, 2021

NCTN group chairs, experts: Diverse representation of minorities in clinical trials and drug development saves lives

November 3, 2021

The role of allostatic load in breast cancer treatment and survival

Tweets

ECOG-ACRIN Cancer Research GroupFollow

Biomarker-driven medical research involving adults who have or are at risk of developing cancer

ECOG-ACRIN Cancer Research Group @eaonc·

21 Jan

During #PancreaticCancer Clinical Trials Awareness Month, learn about studies like EA2185, which is evaluating the clinical effectiveness & resource utilization of two common approaches to pancreatic cyst surveillance. Learn more: http://bit.ly/ea2185-pan-cyst cc: @PanCAN @herbert_zeh

Reply on Twitter 1484609276857491465 Retweet on Twitter 14846092768574914652 Like on Twitter 14846092768574914654 Twitter 1484609276857491465

ECOG-ACRIN Cancer Research Group @eaonc·

21 Jan

Learn about the EA2201 study for patients with MSI-H or dMMR #RectalCancer, testing if #immunotherapy with nivolumab and ipilimumab plus radiation prior to surgery lowers the chance of the cancer growing/spreading. More information: https://bit.ly/ea2201-study

Reply on Twitter 1484541605658902536 Retweet on Twitter 1484541605658902536 Like on Twitter 1484541605658902536 Twitter 1484541605658902536

ECOG-ACRIN Cancer Research Group @eaonc·

20 Jan

#Clinicaltrial EA9181 is testing treatment with steroids and tyrosine kinase inhibitors (TKIs) plus either blinatumomab or chemotherapy for adults with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia (#ALL). https://bit.ly/ea9181-trial #leusm @MRLitzow @PennLeukemia

Reply on Twitter 1484254770072281092 Retweet on Twitter 14842547700722810921 Like on Twitter 1484254770072281092 Twitter 1484254770072281092

Scientific Pursuits

We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More

ECOG-ACRIN by the Numbers

Active Clinical Trials

1300

Participating Institutions

International Sites

15000

Individual Members

Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).